Global Psychiatry Partnering 2012-2018: Deal trends, players and financials

Publisher Name :
Date: 01-Oct-2018
No. of pages: 700
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Psychiatry Partnering 2012-2018: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the psychiatry partnering deals and agreements entered into by the worlds leading healthcare companies

Global Psychiatry Partnering 2012 to 2018 provides the full collection of Psychiatry disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Trends in Psychiatry partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Psychiatry partnering agreement structure

Psychiatry partnering contract documents

Top Psychiatry deals by value

Most active Psychiatry dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Psychiatry deals.

The report presents financial deal terms values for Psychiatry deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Psychiatry dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Psychiatry dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Psychiatry deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Psychiatry dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Psychiatry deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Psychiatry partnering deals by specific Psychiatry target announced since 2012. The chapter is organized by specific Psychiatry therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Psychiatry partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Psychiatry partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Psychiatry technologies and products.

Report scope

Global Psychiatry Partnering 2012 to 2018 is intended to provide the reader with an in-depth understanding and access to Psychiatry trends and structure of deals entered into by leading companies worldwide.

Global Psychiatry Partnering 2012 to 2018 includes:

Trends in Psychiatry dealmaking in the biopharma industry since 2012

Analysis of Psychiatry deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Psychiatry deal contract documents

Comprehensive access to over 3500 Psychiatry deal records

The leading Psychiatry deals by value since 2012

Most active Psychiatry dealmakers since 2012

The report includes deals for the following indications: Akathisia, Anxiety disorder, Generalised anxiety disorder, Panic disorder, Post traumatic stress disorder, Attention deficit hyperactivity disorder, Bipolar disorder, Chronic fatigue syndrome, Cognitive impairment, Delirium, Dementia, Alzheimers, Dementia with lewy bodies, Vascular dementia, Depression, Dystonia, Eating disorder, Anorexia, Bulimia, Learning disability, Aspergers, Autism, Mania, Obsessive compulsive disorder, Personality disorder, Schizophrenia, Sleep disorders, Insomnia, Narcolepsy, Sleep apnoea, Tardive dyskinesia, Tourettes, plus other psychiatric indications.

In Global Psychiatry Partnering 2012 to 2018, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Psychiatry Partnering 2012-2018 report provides comprehensive access to available deals and contract documents for over 600 psychiatry deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Psychiatry Partnering 2012 to 2018 provides the reader with the following key benefits:

In-depth understanding of Psychiatry deal trends since 2012

Access Psychiatry deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Psychiatry partner companies

Comprehensive access to over 750 links to actual Psychiatry deals entered into by the world's biopharma companies

Indepth review of Psychiatry deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Psychiatry opportunities

Uncover companies actively partnering Psychiatry opportunities

Global Psychiatry Partnering 2012-2018: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Psychiatry dealmaking
2.1. Introduction
2.2. Psychiatry partnering over the years
2.3. Psychiatry partnering by deal type
2.4. Psychiatry partnering by industry sector
2.5. Psychiatry partnering by stage of development
2.6. Psychiatry partnering by technology type
2.7. Psychiatry partnering by therapeutic indication

Chapter 3 -Financial deal terms for Psychiatry partnering
3.1. Introduction
3.2. Disclosed financials terms for Psychiatry partnering
3.3. Psychiatry partnering headline values
3.4. Psychiatry deal upfront payments
3.5. Psychiatry deal milestone payments
3.6. Psychiatry royalty rates

Chapter 4 - Leading Psychiatry deals and dealmakers
4.1. Introduction
4.2. Most active in Psychiatry partnering
4.3. List of most active dealmakers in Psychiatry
4.4. Top Psychiatry deals by value

Chapter 5 - Psychiatry contract document directory
5.1. Introduction
5.2. Psychiatry partnering deals where contract document available

Chapter 6 - Psychiatry dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Psychiatry therapeutic target

Appendices
Appendix 1 - Directory of Psychiatry deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Psychiatry deals by deal type 2012 to 2018
Appendix 3 - Directory of Psychiatry deals by stage of development 2012 to 2018
Appendix 4 - Directory of Psychiatry deals by technology type 2012 to 2018
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Tables and Figures

Figure 1: Psychiatry partnering since 2012
Figure 2: Psychiatry partnering by deal type since 2012
Figure 3: Psychiatry partnering by industry sector since 2012
Figure 4: Psychiatry partnering by stage of development since 2012
Figure 5: Psychiatry partnering by technology type since 2012
Figure 6: Psychiatry partnering by indication since 2012
Figure 7: Psychiatry deals with a headline value
Figure 8: Psychiatry deals with upfront payment values
Figure 9: Psychiatry deals with milestone payment
Figure 10: Psychiatry deals with royalty rates
Figure 11: Active Psychiatry dealmaking activity- 2012 to 2018
Figure 12: Top Psychiatry deals by value since 2012
  • Global Divalproex Sodium Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 81
    Divalproex Sodium is used to treat certain types of seizures (epilepsy). This medicine is an anticonvulsant that works in The brain tissue to stop seizures. Divalproex Sodium is also used to treat The manic phase of bipolar disorder (manic-depressive illness), and helps prevent migraine headaches. This medicine is available only with your doctor's prescription. The global Divalproex Sodium market was valued at US$ 2188.5 million in 2023 and is anticipated to reach US$ 33......
  • Global Divalproex Sodium Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 90
    According to our LPI (LP Information) latest study, the global Divalproex Sodium market size was valued at US$ 2140.9 million in 2023. With growing demand in downstream market, the Divalproex Sodium is forecast to a readjusted size of US$ 3312 million by 2030 with a CAGR of 6.4% during review period. The research report highlights the growth potential of the global Divalproex Sodium market. Divalproex Sodium are expected to show stable growth in the future market. However, product differ......
  • Global Quetiapine Fumarate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115
    According to our LPI (LP Information) latest study, the global Quetiapine Fumarate market size was valued at US$ 156.2 million in 2023. With growing demand in downstream market, the Quetiapine Fumarate is forecast to a readjusted size of US$ 132.9 million by 2030 with a CAGR of -2.3% during review period. The research report highlights the growth potential of the global Quetiapine Fumarate market. Quetiapine Fumarate are expected to show stable growth in the future market. However, produ......
  • Global Clozapine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 114
    According to our LPI (LP Information) latest study, the global Clozapine market size was valued at US$ 341.4 million in 2023. With growing demand in downstream market, the Clozapine is forecast to a readjusted size of US$ 463.4 million by 2030 with a CAGR of 4.5% during review period. The research report highlights the growth potential of the global Clozapine market. Clozapine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and s......
  • Global Trazodone Hydrochloride (API) Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 92
    According to our LPI (LP Information) latest study, the global Trazodone Hydrochloride (API) market size was valued at US$ million in 2023. With growing demand in downstream market, the Trazodone Hydrochloride (API) is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Trazodone Hydrochloride (API) market. Trazodone Hydrochloride (API) are expected to show stable growth in the future......
  • Global Trazodone Hydrochloride (API) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 93
    According to our (Global Info Research) latest study, the global Trazodone Hydrochloride (API) market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period. Trazodone, a phenylpiperazine-triazolopyridine antidepressant, was originally discovered and developed in Italy in the 1970s by Angelini research laboratories. Trazodone is used to treat depression and to treat the combination of symptoms of anxiety an......
  • Global Divalproex Sodium Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 91
    According to our (Global Info Research) latest study, the global Divalproex Sodium market size was valued at USD 2251.9 million in 2023 and is forecast to a readjusted size of USD 3371.1 million by 2030 with a CAGR of 5.9% during review period. Divalproex Sodium is used to treat certain types of seizures (epilepsy). This medicine is an anticonvulsant that works in the brain tissue to stop seizures. Divalproex Sodium is also used to treat the manic phase of bipolar disorder (manic-d......
  • Global Risperidone Market Research Report 2023
    Published: 28-Dec-2023        Price: US 2900 Onwards        Pages: 93
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Risperidone market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Janssen (Johnson & Johnson) - Ajanta Pharma - Amneal Pharmaceuticals - Aurobindo Pharma - Hikma - Sandoz - Lannett - Tris Pharma - Ap......
  • Global Schizophrenia Therapeutics Market Status and Outlook 2023-2028
    Published: 27-Dec-2023        Price: US 3160 Onwards        Pages: 101
    Schizophrenia is usually treated with an individually tailored combination of talking therapy and medicine. Most people with schizophrenia are treated by community mental health teams (CMHTs). The goal of the CMHT is to provide day-to-day support and treatment while ensuring you have as much independence as possible. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market va......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs